PFE — PFIZER INC

NYSE · Health Care · Pharmaceuticals · CIK 78003 ·
Last close
$24.72
Market Cap
$140.89B
52W High
$28.28
52W Low
$24.69
ADV30
38,670,470
Next earnings
2026-08-04
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 14,450,000,000 10,902,000,000 4,131,000,000 2,687,000,000 207,618,000,000 1,703,000,000 117,214,000,000
Dec 2025 17,557,000,000 12,285,000,000 3,475,000,000 -1,648,000,000 208,160,000,000 1,142,000,000 121,385,000,000
Sep 2025 16,654,000,000 12,482,000,000 4,137,000,000 3,541,000,000 208,731,000,000 1,343,000,000 115,635,000,000
Jun 2025 14,653,000,000 10,875,000,000 3,765,000,000 2,910,000,000 206,095,000,000 1,638,000,000 117,083,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$11,961,000,000
Investing CF
$-3,841,000,000
Financing CF
$-7,932,000,000
CapEx
$-2,501,000,000
Dividends Paid
$-9,779,000,000
Buybacks
EPS Diluted TTM
$1.31
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$117,238,000,000
Inventory
$10,667,000,000
Receivables
$16,173,000,000
ST Investments
$11,372,000,000
EBIT TTM
$10,591,000,000
Pretax Income TTM
$7,906,000,000
Interest Exp TTM
$2,685,000,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$63,315,001,344
EBITDA
$25,460,000,768
Free Cash Flow
$12,376,625,152
Enterprise Value
$192,843,251,712
Total Cash
$13,080,999,936
Total Debt
$64,731,000,832
Shares Out
5,699,444,169
Trailing EPS
$1.31
Book Value
$15.81
ROE
8.3%
ROA
5.7%
Div Yield
6.96%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 62,579,000,000 15,794,000,000 7,771,000,000 208,160,000,000 121,385,000,000 11,704,000,000
Dec 2024 63,627,000,000 14,830,000,000 8,031,000,000 213,396,000,000 124,899,000,000 12,744,000,000
Dec 2023 59,554,000,000 4,223,000,000 2,119,000,000 226,501,000,000 137,213,000,000 8,700,000,000
Dec 2022 101,175,000,000 37,164,000,000 31,372,000,000 197,205,000,000 101,289,000,000 29,267,000,000

TTM Snapshot

Revenues TTM
$77,866,000,000
NetIncome TTM
$18,837,000,000
OpCashFlow TTM
$0
Assets (Latest)
$213,396,000,000
Forward EPS
$2.83

Max Pain — expiry 2026-06-26

max pain strike: $25.50 · spot: $24.16 · call oi: 80,710 · put oi: 40,089
Expected Move to 2026-06-26: ±$0.44 (1.82%) — implied range $23.72$24.60 · ATM straddle on $24.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NONOF NOVO NORDISK A S $154.49B $46.09
ABT ABBOTT LABORATORIES $157.69B $90.53
NVO NOVO NORDISK A S $158.95B $47.42
VRTX VERTEX PHARMACEUTICALS INC / MA $118.89B $468.42
BMY BRISTOL MYERS SQUIBB CO $113.40B $55.53

News headlines (Yahoo Finance, 1h cache)

Update: Market Chatter: Pfizer Dismissed From US States' Lawsuit on Generic Drug Price Fixing
2026-06-24 18:52 · Yahoo
FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
2026-06-24 18:10 · Yahoo
Can a Former Pfizer Executive Catalyze Nike’s Sluggish Turnaround?
2026-06-24 15:29 · Yahoo
Nike names former Pfizer CFO David Denton as finance chief
2026-06-24 14:54 · Yahoo
LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?
2026-06-24 12:59 · Yahoo
Nike names Pfizer CFO David Denton to replace Matthew Friend
2026-06-24 12:35 · Yahoo
Zacks Investment Ideas feature highlights: IBB, Novartis, Pfizer and Eli Lilly's
2026-06-24 08:28 · Yahoo
Nike (NKE) Names David Denton CFO As Turnaround Pressure Builds
2026-06-23 23:11 · Yahoo
NKE Stock Gains 2% After-Hours As Nike Names New CFO, Reaffirms Outlook — Retail Calls Leadership Transition ‘Promising’
2026-06-23 22:01 · Yahoo
Nike Discloses CFO Transition
2026-06-23 21:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.